

Brief Interview with Dr. Charles J. Malemud (Editor-in-Chief)

Journal of Clinical & Cellular Immunology

1. What is the research topic you are working on now?

The role that chondrocyte signal transduction plays in regulating matrix metalloproteinase gene expression and apoptosis in arthritis.

2. How many years have you been associated with the current research?

44 years.

3. What are the attributes for a quality article?

Conclusions are supported by data.

4. Do you have any research funding (NIH or other national funding) now?

Yes, PI: Genentech; Consultant/Collaborator: NICHD; Collaborator: NEI.

5. When did you become an editor of OMICS Journal?

2010-Member, Editorial Board, 2012-Editor-in-Chief.

6. Where can the journal find the maximum scope in terms of niche?

Basic research papers that connect fundamental studies in cellular immunology with a clinical problem (e.g. arthritis; multiple sclerosis; irritable bowel diseases including Crohn's disease).

7. What is your greatest career accomplishment?

We discovered that chondrocytes produce matrix metalloproteinases (MMPs) which are the cause of cartilage destruction in arthritis (between 1980-1981 with continuing studies to date).

8. How does the published scientific content assist the potential researchers?

Provides a platform for establishing what background literature exists which enables researchers to move forward with a scientific study.

9. What is the purpose of serving as an editor?

Find suitable peer-reviewers; Make final decisions regarding suitability of peer-reviewed papers for publication.

10. Do you have any patents?

No.

11. Have you contributed any editorials or papers (any types) to OMICS Journals in the past two years?

Yes.

12. Do you plan to contribute any editorials or papers to OMICS Journals in the next year?

IF REQUESTED.

13. How would you define your experience with OMICS Group?

Peer-review process is well-managed. Editorial decision making is straightforward.

However, there has been a significant lag time from when invoices are submitted to my institution for payment of "page processing charges" and eventual payment to OMICS.

14. Your opinion on conducting Editorial Board meetings at related Conferences?

Each OMICS journal may have specific issues. Thus, each Editorial Board should meet separately.

15. Would you recommend OMICS to your friends or colleagues?

I continue to promote the JCCI to my colleagues. However, the fact that the JCCI papers are not automatically entered in the PubMed database has been an impediment.

16. How do you differentiate Journal of Clinical & Cellular Immunology with other journals in the field?

The JCCI has provided an opportunity for young investigators to receive a fair and impartial peer-review. I think this is one characteristic of the JCCI that distinguishes it from other society-based immunology journals.